Dogwood State Bank (DSBX)

OTCMKTS · Delayed Price · Currency is USD
15.50
+0.28 (1.84%)
Feb 4, 2025, 11:59 AM EST
-6.34%
Market Cap 296.03M
Revenue (ttm) 67.43M
Net Income (ttm) 5.87M
Shares Out 18.98M
EPS (ttm) 0.35
PE Ratio 44.57
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 3,404
Open 15.40
Previous Close 15.22
Day's Range 15.40 - 15.60
52-Week Range 12.75 - 17.00
Beta 0.04
RSI 66.45
Earnings Date Jan 31, 2025

About Dogwood State Bank

Dogwood State Bank provides banking products and services for businesses, business owners, professionals, and their employees in North Carolina. It offers personal and business checking accounts; savings accounts; money market accounts; individual retirement accounts; and certificates of deposit. The company also provides business financing services, including business lines of credit and business term loans; personal lines of credit; overdraft protection services; credit cards; home equity lines; personal loans comprising automobile and truck ... [Read more]

Sector Financials
Founded 2001
Employees 33
Stock Exchange OTCMKTS
Ticker Symbol DSBX
Full Company Profile

Financial Performance

In 2024, Dogwood State Bank's revenue was $67.43 million, an increase of 38.97% compared to the previous year's $48.52 million. Earnings were $5.87 million, a decrease of -44.84%.

Financial Statements

News

Dogwood State Bank Reports Fourth Quarter and Full Year 2024 Results

RALEIGH, N.C. , Jan. 23, 2025 /PRNewswire/ -- Dogwood State Bank (OTC: DSBX) ("Dogwood" or the "Bank") announced today its financial results for the three and twelve months ended December 31, 2024.

12 days ago - PRNewsWire

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav...

14 days ago - GlobeNewsWire

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the “Comb...

3 months ago - GlobeNewsWire

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024

ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today th...

3 months ago - GlobeNewsWire

Dogwood State Bank Reports Third Quarter 2024 Results and Successful Integration of Community First

RALEIGH, N.C. , Oct. 23, 2024 /PRNewswire/ -- Dogwood State Bank (OTC: DSBX) ("Dogwood" or the "Bank") announced today its financial results for the three and nine months ended September 30, 2024.

3 months ago - PRNewsWire

Dogwood State Bank Reports Higher Second Quarter 2024 Earnings Reflecting Strong Operating Momentum Heading into Community First Acquisition

RALEIGH, N.C. , July 30, 2024 /PRNewswire/ -- Dogwood State Bank (OTCQX: DSBX) ("Dogwood") announced today its financial results for the three and six months ended June 30, 2024 as it prepares to clos...

6 months ago - PRNewsWire